Accessibility to Essential Medicines in New York City by Zip Code Income Levels and Boroughs by Aronson, Yan & Addo-Atuah, Joyce
Volume 4 | Number 3 Article 127
2013
Accessibility to Essential Medicines in New York
City by Zip Code Income Levels and Boroughs
Yan Aronson
Joyce Addo-Atuah
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Aronson Y, Addo-Atuah J. Accessibility to Essential Medicines in New York City by Zip Code Income Levels and Boroughs. Inov
Pharm. 2013;4(3): Article 127. http://pubs.lib.umn.edu/innovations/vol4/iss3/10
Student Paper PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                  2013, Vol. 4, No. 3, Article 127                               INNOVATIONS in pharmacy   1 
 
Accessibility to Essential Medicines in New York City by Zip Code Income Levels and Boroughs 
Yan Aronson, PharmD
1
, Joyce Addo-Atuah, PhD
2 
1
Was a PharmD candidate, 2013, at the Touro College of Pharmacy, New York, at the time of this study which was the required 
students’ Capstone Project. 
 2 
Associate
 
Professor of Pharmacy & Health Outcomes and the student’s Capstone Project Advisor.  
 
Keywords: Access to medicines, medication access, prescription drugs, medication costs, medication prices, frequently prescribed 
medicines, availability of medicines, New York City. 
 
Abstract 
Access to essential medicines is fundamental to medication adherence, continuity of care and hence population health outcomes and 
overall quality of life. Disparities in the availability and the cost of these medications in New York City, especially for low income 
neighborhoods, would compound the underlying health disparities in these neighborhoods. This study examined the physical and 
financial accessibility to 8 of the 150 Most Frequently Prescribed Drugs in New York, 2 each for Asthma, Diabetes, Hypertension, and 
Hyperlipidemia, 4 conditions that are among the top 10 most costly conditions in the United States. The study did not find any 
significant differences in mean drug prices between the high, medium, and low income neighborhoods in the City. However, the 
significantly different income levels and uninsured rates across neighborhood income strata in the City (p<0.001 for both), coupled 
with the high disease burden and other underlying disparities in low income neighborhoods, would point to potential affordability 
challenges for needed medications in these neighborhoods. On the other hand, significant differences in mean prices between the 5 
City boroughs were found for 3 of the study drugs: Advair
®
, p=0.009; Amlodipine 10mg, p<0.001; and Lisinopril 10mg, p=0.046. No 
such significant differences were observed for the mean prices of the other 5 study drugs-Proventil HFA,
® 
Metformin HCL 500mg, 
Glipizide ER 5mg, Simvastatin 20mg, and Atorvastatin 10mg.  The study findings did not also suggest that drug prices are dictated by 
the number of pharmacies in a neighborhood. 
 
Further studies would be needed to better understand the complexities associated with the accessibility of essential medicines in New 
York City. These studies could include qualitative ones which would examine the perceptions and experiences of City residents with 
respect to the accessibility of prescribed medications as the basis for targeted interventions directed at promoting access to needed 
medications for all New Yorkers. 
 
Introduction 
Essential medicines have been defined as “those that satisfy 
the priority health care needs of the population.”
1  
In the 
United States
2-5
as a whole and also in the State 
6
and City
7
 of 
New York, the high morbidity and mortality associated with 
costly health conditions such as asthma, diabetes, 
hypertension, hyperlipidemia and their complications, qualify  
the medicines for the treatment of these conditions to be 
labeled as “essential medicines.”
1
 Access to essential 
medicines have been defined as their continuous availability 
and affordability in public or private health facilities or 
pharmacies within a reasonable distance from the homes of 
those who need them.
8 
 Equitable access to safe and 
affordable medicines is considered to be of the utmost 
importance by the global health community.
9 
Four main dimensions of access to essential medicines,  
 
Corresponding Author: Yan Aronson, PharmD
1 
4742 Burnet Ave, Sherman Oaks, CA 91403 
Phone: (818) 398-8818; Email: yan624@yahoo.com 
 
vaccines, and other health commodities have been identified  
and operationalized.
10 
They consist of: (a) Physical 
Availability, (b) Affordability [financial accessibility], (c) 
Geographic Accessibility, and (d) Acceptability [satisfaction].
10 
Physical availability has been defined as the relationship 
between the type and quantity of product(s) or service(s) 
needed and the product(s) or service(s) actually provided. 
Some of the key indicators proposed for physical availability 
include:  percentage of a set of unexpired key items in stock, 
percentage of time out of stock for a set of key items.
10 
Affordability defines the relationship between prices of the 
products or services and the user’s ability to pay for them. 
Key indicators proposed for affordability include the average 
price differential between a generic and brand product for 
the treatment of key health conditions; and public and 
private sector prices as compared to the median international 
prices of drugs for those conditions.
10 
Geographic accessibility on the other hand describes the 
relationship between the location of the product or service 
and the location of the eventual user of the product or 
service.
10 
Some key indicators include the percentage of 
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households located more than five kilometers from a health 
facility or pharmacy that has a set of key items in stock at all 
times.
10 
Acceptability (or satisfaction), defines the 
relationship between the user’s attitudes and expectations 
about the products and services and the actual 
characteristics of products and services. Key indicators for 
this dimension include clients’ satisfaction with outcome of 
their most recent visit to the pharmacy or other outlets for 
their medications.
10  
Barriers to accessing needed medications are a global public 
health concern.  Reports from global monitoring indicate that 
only 51.8% of public and 68.7% of private health facilities in 
developing countries were able to provide essential 
medicines to their populations in 2012.
9   
High medicine
 
prices 
have been identified as one such barrier to medication access 
in these countries. Essential medicines, when available, were 
found to have prices that were between 2.5-6.5 times those 
of their international reference prices (IRPs).
9 
Although 
generic equivalent drugs are much cheaper than their 
innovator brands, they may not always be available, 
especially in the private sector in these countries.
9  
 
The 8 Millennium Development Goals (MDGs), which provide 
a framework for promoting global health in the context of 
development, has a specific target-Target 8E of  MDG 8-which 
addresses access to essential medicines.
11 
Target 8E seeks to 
promote  access to essential medicines for the populations in 
developing countries through global cooperation between 
pharmaceutical companies and the governments of these 
countries.
11 
The indicator for monitoring progress for this 
target is, “Proportion of the population with access to 
affordable essential medicines on a sustainable basis.
11  
 
Medication access is also very relevant to the United States 
population; several factors can create gaps in the accessibility 
to medications for those who need them. These include 
affordability challenges arising from lack of health insurance 
coverage which necessitates people having to pay for their 
medications out-of-pocket
12
 However, even  individuals with 
health insurance coverage may face prescription drug 
accessibility challenges as a result of the use of various 
prescription drugs utilization management strategies by their 
health plans.
13-14
 These strategies include prior authorization, 
stepped therapy, with increasing out-of-pocket payments for 
higher tier drugs, full payment for non-formulary drugs, and 
utilization reviews.
13-14
. Seniors in America faced affordability 
challenges for their outpatient prescription drugs before the 
implementation of the Medicare Part D program in 2006.
15 
It 
is important to note however, that the Part D program was 
designed such that Medicare beneficiaries would have to pay 
for their full outpatients prescription drug costs out-of-pocket 
once they hit the coverage gap, commonly referred to as the 
“donut hole.”
16 
This could have serious implications for 
prescription drugs accessibility, and hence by inference 
medication adherence and outcomes, for the Medicare 
population in most need of medications. Fortunately, this 
accessibility challenge is being addressed by the Affordable 
Care Act of 2010 with the ultimate aim of eliminating the 
“donut hole” in the Part D Program.
17
  
 
With the goal of addressing the escalating expenditures on 
prescription drugs for public programs like Medicaid, many 
states have been promoting generic prescribing and 
empowering pharmacists to substitute generically equivalent 
drugs for branded products in the absence of any 
contraindication.
18-21  
Although generic drugs can bring 
consumers significant savings, they may not be as readily 
available as their brand-name innovator equivalents.
21 
People 
in neighborhoods where needed generics are not available 
would have no option but to pay the higher prices for brand 
name drugs; those with the means may have to travel 
distances to obtain needed generics. However, generic drug 
shortages in the United States are increasingly becoming 
problematic; about 251 such shortages were recorded in 
2011 alone.
22 
In a study by Baumer et al on drug shortages in 
acute care hospitals,
23
 nearly all pharmacy directors surveyed 
believed that shortages had changed practice and had 
compromised patient care. Their results suggested that 
shortages increase the acquisition cost of pharmaceuticals in 
the United States by over $99 million annually.
23 
In another 
study which looked at the impact of drug shortages on U.S. 
health systems, most respondents surveyed felt that the 
information resources available to manage drug shortages 
were not adequate, costing the U.S. $216 million annually in 
labor costs to manage the shortages.
24 
 
High prescription drug prices are a significant barrier to 
appropriate medication use especially among populations 
with limited resources. This can potentially compromise 
medication adherence and thus the health outcomes of 
vulnerable and under-served populations.   
In the state of New York, the Drug Retail Price List Law 
mandates pharmacies to (1) maintain a price list for the 150 
Most Prescribed Medicines in the state, (2) update this list 
weekly, (3) post a sign in the pharmacy informing clients of 
the availability of this list, and (4) make copies available to 
consumers upon request.
25
 This Law was intended to make 
the above information available to consumers so that they 
could lower their drug costs by shopping around for 
competitive prices.
25 
However, studies by the New York City 
Council Investigation Division in both 2002 and 2004 reported 
widespread noncompliance to the Law; more importantly, 
there was no indication of any serious enforcement-
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enhancing changes between the 2 year period.
25  
The 2004 
City investigation, for example, found gross disparities 
between drug prices within and between New York City 
boroughs; some drug price differences ranged from $30 to 
$80.
25 
Furthermore, only about 28% of pharmacies had actual 
Drug Price Lists and 70% of pharmacies did not comply with 
the requirement to make their Drug Price Lists available to 
consumers on request.
25  
The researchers recommended that 
properly enforcing the State Law on Drug Retail Price Lists 
and making these prices available online could potentially 
make drug prices in the City become more transparent and 
competitive for the benefit of consumers.
25  
Another study in 
New York City has reported significant disparities in 
geographic access to neighborhood pharmacies and the 
availability of commonly-prescribed medications across 
neighborhood income levels.
26
 Commonly-prescribed 
medications were found to be more likely out of stock , 
OR=1.24; 95% CI (1.02-1.52) in poorer neighborhoods than in 
the medium and higher income ones.
26 
Entire  neighborhoods 
could be described as “medication deserts” because both 
geographic access to pharmacies and the availability of 
common medications were very poor in these communities, 
according to this study.
26
 Significant differences were also 
reported in the relative proportion of independent to chain 
pharmacies across neighborhood incomes in the City.
26
  
 
Another study conducted by Gellad et al in Florida, using 
available state drug prices data, sought to determine whether 
there were significant differences in retail drug prices based 
on neighborhood income strata.
27 
Their findings indicated 
that mean drug prices were 9% above the statewide average 
in the poorest zip codes.
27
More importantly, mean drug 
prices in the independent pharmacies in the poorest zip 
codes were about 15% higher than those in the chain 
pharmacies.
27   
 
In the context of the Healthy People 2020 goal of achieving 
health equity, eliminating disparities, and improving the 
health of all population groups,
28
 and given the great 
disparities in incomes among the very diverse populations of 
NYC, examination of the accessibility to essential medicines in 
the City is of important public health relevance. This study 
therefore sought to evaluate 2 dimensions of accessibility 
(physical availability and drug prices/financial) to essential 
medicines in New York City by answering the following 
research questions: 
 
1) Are there significant differences in mean drug prices 
across neighborhood income levels and boroughs in 
New York City?  
2) Are drug prices in a zip code associated with the 
number of pharmacies in the zip code? 
Methods 
This was a cross sectional study of mean drug prices by zip 
code income levels and boroughs (The Bronx, Brooklyn, 
Manhattan, Queens, and Staten Island) in New York City. “Zip 
code definitions of New York City Neighborhoods” available 
on the website of the New York State Department of Health 
was used to identify the zip codes in the 5   New York City 
boroughs.
29
 The NYC Census Fact Finder website and the 
EpiQuery search engine of the New York City Department of 
Health and Mental Hygiene provided neighborhood 
characteristics including the mean household income, the 
predominant racial/ethnic group of the resident population 
based on the 2000 and 2010 census data, and the percentage 
of the population uninsured in the neighborhoods.
30-31
 
 
For the purposes of this study and in an effort to adequately 
cover the wide range of mean household incomes reported 
for the neighborhoods in NYC, zip codes or neighborhoods 
were categorized as high income ones if the mean household 
incomes were greater than or equal to $80,000; medium 
income ones were those below $80,000 but above $57,000; 
and low income neighborhoods were those with mean 
household incomes below $57,000. Within each NYC 
borough, 2 zip codes each were randomly selected from the 
high, medium, and low income neighborhoods, yielding a 
total of 30 zip codes (6 per borough) for the study. 
 
Two prescription medications each for Asthma, Diabetes, 
Hypertension, and Hyperlipidemia were targeted for the 
study. The targeted medical conditions are among the most 
costly conditions in the United States according to the 
Medical Expenditure Panel Survey.
5
  
The specific study drugs, selected from the “150 Most 
Frequently Prescribed Drugs in New York State,” which is 
published annually by the New York State Board of 
Pharmacy,
32 
were: 
 
Asthma: Advair Diskus® 250/50 (GlaxoSmithKline) 
[Fluticasone propionate 250 mcg & Salmeterol 50 mcg] and 
Proventil HFA Inhaler® 6.7gm (MERCK & Co) [Albuterol 
sulfate] 
Diabetes: Metformin HCL 500mg and Glipizide ER 5mg 
Hypertension: Amlodipine 10mg and Lisinopril 10mg 
Hyperlipidemia: Atorvastatin 10mg and Simvastatin 20mg 
 
The “Prescription Drug Prices in New York State” search 
engine on the New York State Department of Health’s 
webpage 
33
 was used to collect data on drug prices. The 
search engine allows for the selection of drugs of interest, 
target zip code(s), and the distance around the zip code(s) in 
order to generate a list of the names and number of 
pharmacies,   along with their drug prices, in the selected zip 
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code(s). We chose a 2-mile radius around the target zip codes 
for the search on drug prices in this study. From the list of 
available pharmacies in each zip code so generated, we 
calculated the mean prices for the study drugs in that zip 
code by averaging drug prices from 2 randomly-selected 
chain (Rite Aid and Walgreens) and 2 independent 
pharmacies from that neighborhood. The mean drug prices so 
determined were for 1 inhaler each (Advair
® 
and Proventil 
HFA
®
) and for 30 tablets each of Glipizide ER 5mg, Amlodipine 
10mg, Lisinopril 10 mg, Simvastatin 20, Atorvastatin 10mg 
and for 60 tablets of Metformin HCL 500mg.
32  
Advair® and 
Proventil
®
 are listed as such on the list of 150 Most Prescribed 
Drugs; the other 6 drugs have been listed by their generic 
names with an indication of their innovator brand names.
32 
 
 
Data Analysis 
Data collected for each zip code included neighborhood 
demographics, drug prices, and the number of pharmacies 
available within a 2-miles radius of each zip code. 
Neighborhood data covered zip codes with their associated 
cities and boroughs. Zip code demographic data consisted of 
population size, predominant racial/ethnic group, socio-
economic status (expressed as mean household income) and 
percent of population uninsured in 2010.  
To determine whether there were significant differences in 
mean drug prices by zip code household income in NYC, we 
pooled the mean drug prices in the 3 zip code income levels 
across the City, coming out with City-wide mean prices for 
each drug in the high, medium, and low City neighborhoods 
and compared them for significant differences using One Way 
Analysis of Variance (ANOVA). We also used ANOVA to 
analyze differences in mean drug prices across the 5 NYC 
boroughs. The strength and the direction of the relationships 
between the number of pharmacies in a neighborhood and 
mean drug prices were examined by Pearson Product-
Moment Correlation. All statistical tests were performed 
using IBM SPSS Statistics 19 software package (IBM 
Corporation, Armonk, NY).  P-values for statistical test results 
≤ 0.05 were taken as indicative of statistically-significant 
differences or relationships between the study variables.  
 
Results 
Table 1 gives the demographic characteristics of the 
populations in the 30 study zip codes in New York City and 
the number of pharmacies within a 2-mile radius of each zip 
code. The information in Table 1 is summarized in Table 2. 
Mean prices of the study drugs with their corresponding zip 
codes and NYC boroughs, household income levels, and the 
number of pharmacies are presented in Table 3. 
 
The mean (95% CI) prices of the study drugs across 
neighborhood income levels in the City have been presented 
in Table 4. Mean prices (95% CI) of Advair®250/50 inhaler 
was found to be $290.44($284.62-$296.26), $293.02 
($284.75-$301.29), and $295.15($286.92-$303.38) in the 
high, medium, and low income neighborhoods, respectively. 
No statistically significant differences in these prices were 
observed (p=0.689). Similarly, the mean prices of the 
remaining 7 study drugs were not found to be significantly 
different across neighborhood income strata in the City 
(Table 4). Table 5 presents the mean drug prices across the 5 
NYC boroughs. Among the 8 study drugs, only 3 of them 
(Advair
®
250/50 inhaler, Amlodipine 10mg, and Lisinopril 
10mg), were found to have mean prices that varied 
significantly across the boroughs. Whereas 
Advair
®
250/50mg’s mean price was $289.36($281.86-
$296.96) in the Bronx, it was $294.39 ($284.14-$304.62), 
$299.05 ($290.20-$307.90), $280.74($ 272.61-$288.11), and 
$301.03($298.30-$304.10) in Brooklyn, Manhattan, Queens, 
and Staten Island, respectively (p=0.009). Similarly, 30 tablets 
of Amlodipine 10mg ranged from $44.48 ($$42.75-$46.21) in 
the Bronx to $63.49 ($62.19-$64.79) in Staten Island 
(p<0.001). Furthermore, Lisinopril 10mg prices were found to 
differ significantly across boroughs (p=0.0406). 
 
Given that an earlier study by Amstislavski et al
26 
had 
reported significant disparities in geographic access to 
neighborhood pharmacies across neighborhood income 
strata in the City, this study further sought to determine 
whether there were significant correlations  between mean 
drug prices in New York City neighborhoods and the number 
of pharmacies within a 2-mile radius of the neighborhood. 
Positive linear relationships of varying strengths were 
observed between the number of pharmacies and the mean 
prices of 4 of the study drugs but none achieved statistical 
significance-Advair
®
 (r=0.53; p=0.643); Proventil HFA
®
 (r=0.62; 
p=0.575); Glipizide ER 5mg (r=0.086; p=0.945); and 
Simvastatin 20mg (r=0.394; p=0.742). The mean prices of the 
remaining 4 study drugs were negatively correlated to the 
number of pharmacies in the neighborhood but again, none 
of these relationships were found to be statistically 
significant.  
 
Discussion 
Prices of essential medicines determine their affordability 
(financial accessibility) which in turn may have major 
implications for medication adherence, continuity of care, 
and hence population health outcomes. Significant price 
differences for frequently-prescribed medications for 4 of the 
most common and costly medical conditions in the United 
States-asthma, diabetes, hypertension, and hyperlipidemia-
will undoubtedly compound the challenges of health 
disparities which the United States is already grappling with. 
Such drug price variations in NYC, with its very diverse 
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racial/ethnic, income, and uninsured rates, among others, will 
be even more problematic.  
 
It is gratifying therefore to note that, unlike the Florida study 
of mean drug prices by Gellad et al,
27 
the findings in this 
current study, of mean drug prices by neighborhood income 
levels and boroughs in NYC, did not reveal any significant 
differences in drug prices between the high, medium, and low 
income neighborhoods in the City.  However, attention 
should be drawn to the differences in the mean household 
income levels across the 3 neighborhood income strata in the 
City. Whereas a low income neighborhood (10453) in Morris 
Heights in the Bronx has a mean household income of $37, 
383, that of a similar neighborhood (10303) in Mariner’s 
Harbor in Staten Island is $54,956. Similarly, a high income 
neighborhood (10464) in Pelham Bay in the Bronx has a mean 
household income of $81,856, compared to that of a similar 
neighborhood (10038) in Seaport, Manhattan of $124, 271. 
More importantly, mean household income levels, especially 
in the low income strata, in Staten Island were found to be 
outliers when compared with those in the other 4 boroughs 
in the City. For example, a low income zip code (10302) in 
Staten Island has a mean household income of $56,518, 
which is equivalent to that of a medium income ($56,838) zip 
code (10466) in the Bronx. These income differences were 
statistically significant (p<0.001). In addition to these income 
differences, the percentage of the population without health 
insurance coverage in the high, medium, and low income 
neighborhoods were also significantly different (p<0.001); 
they were 8.80%, 15.76% and18.74%, respectively, in 2010.
12
 
Unlike the insured populations, those uninsured would have 
to pay for their needed medications at the full undiscounted 
retail prices out of pocket, in the absence of any other 
assistance. Health insurance plans normally negotiate with 
drug manufacturers for discounted prices; a benefit that will 
not be available to the uninsured.  
 
Another factor for consideration is the differences in the 
predominant racial/ethnic composition of the resident 
populations in the 3 neighborhood income levels of the City.  
With the exception of Elm Park (10302) in Staten Island, Table 
1 indicates that the predominant racial/ethnic populations in 
the low income neighborhoods in all 5 boroughs of the City 
are African Americans or Hispanics. Hence, low income, along 
with lack of health insurance, in the context of 
disproportionately high disease burden, poor access to health 
care, and poor health outcomes,
34-35 
would suggest a 
potential for medications affordability challenges for these 
populations, even though no significant drug price differences 
were observed across neighborhood income levels in the City.  
 
On the other hand, mean drug prices differed significantly 
across the boroughs for 3 of the 8 study drugs- Advair
®
, 
Amlodipine 10mg and Lisinopril 10mg. However, the price 
differences observed for these drugs in this study did not 
reach the ranges ($30-$80) reported in the City in 2004.
25 
Those researchers suggested that City residents could shop 
for competitive drug prices across boroughs and hence make 
substantial savings.
25 
It is also important to note that 
although the study of Amstislavski et al
26 
reported significant 
disparities in the geographic access to neighborhood 
pharmacies and the availability of commonly-prescribed 
medications across neighborhood income levels in the City, 
the findings in this study would suggest that mean prices of 
prescription medications are not dictated by the number of 
neighborhood pharmacies in NYC.  
 
This study has a number of limitations. Since the New York 
City Council Investigations Division found serious compliance 
challenges with the State Drug Retail Price List Law in 2 
consecutive studies conducted in the City,
25 
it is possible that 
similar challenges still persist, which would mean that the 
drug prices data used in this study may not reflect the most 
current ones in use in the respective pharmacies. Thus 
primary data collection from pharmacies would be important 
to authenticate the reported medication prices. Another 
possible limitation is that only 4 pharmacies per zip code 
were randomly selected for computing the mean prices for 
the 8 study drugs, given the limited time period available for 
the study. A more representative sample of pharmacies, 
systematically selected per zip code may yield a more 
representative data on drug prices in the City.  
 
Conclusion 
Accessibility to essential medicines is fundamental to desired 
medication adherence and optimum outcomes with respect 
to therapeutic benefits of drug treatment and population 
health. Disparities in the geographic access to neighborhood 
pharmacies and also in the physical availability of medications 
and in their costs have been reported in earlier studies 
conducted in NYC.
25-26
 A Florida study has also reported 
significant disparities in mean drug prices across 
neighborhood income strata and between independent and 
chain pharmacies.
27
Although this current study did not find 
any significant differences in drug prices across neighborhood 
income levels in the City, the fact still remains that medicines 
in the United States, especially branded products such as 
Advair
®
 and Proventil HFA
® 
are not cheap.
36
 Whereas insured 
people benefit from their health plans’ negotiated discounted 
drug prices, populations without health insurance coverage 
do not enjoy this luxury. This can be especially problematic 
for, minority, under-served populations already facing 
significant health disparity challenges, 
33-34 
and hence the 
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public health importance and relevance of this study. 
Medicines affordability (financial accessibility) challenges 
could have implications for prescription filling and re-filling, 
medication adherence, and general continuity of care for the 
chronic diseases and conditions targeted in this study, thus 
adversely affecting the health outcomes and quality of life of 
minorities and low income populations in the City. 
Accessibility challenges to the medications targeted in this 
study would have a special public health relevance given that 
they are among the most frequently prescribed for 4 of the 
top 10 most costly conditions among the noninstitutionalized 
adult population 18 years and above in the United States.
5
  
 
Further studies, using a more representative sample of NYC 
zip codes and which also examine differences in mean drug 
prices between chains versus independent pharmacies, 
would be useful. Follow up studies could also be enriched if 
resources would allow for the collection of primary data from 
a representative sample of pharmacies in the City in line with 
the study protocol of Amstislavski et al.
26 
  
 
Furthermore, a qualitative study examining New Yorkers’ 
perceptions of the accessibility of essential medicines and 
their personal experiences of accessing needed prescription 
medications would be needed to assist policy makers, 
healthcare providers and drug manufacturers and distributors 
in taking the requisite steps to promote access to essential 
medications for all populations irrespective of race/ethnicity, 
socio-economic status, and geographic residence in the City. 
Similar qualitative studies on access to medicines, such as the 
one carried out in Ghana,
37 
could  be replicated elsewhere in 
and outside the United States to inform policy and promote 
access. Finally, studies which examine the relationships 
between access to medicines, medication utilization and 
adherence, and health outcomes would be very useful 
towards promoting population health. 
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Table 1.  Demographic Characteristics of Populations in the Study Zip Codes 
 
Zip Code City Borough Income 
Status 
Mean 
Household 
Income ($) 
Population Predominant 
Race/Ethnicity 
% 
Uninsured 
(2010) 
10471 Riverdale Bronx High 104,139 22,922 White 13.8 
10466 Edenwald Bronx Medium 56,838 67,813 African American 13.2 
10453 Morris Heights Bronx Low 37,383 78,309 African American 21.5 
10464 Pelham Bay Bronx High 81,856 4,534 White 11.7 
10461 Morris Park Bronx Medium 63,417 50,502 White 18.1 
10454 Mott Haven Bronx Low 33,417 37,337 Hispanic 21.5 
11231 Carroll Gardens Brooklyn High 101,734 33,336 White 5.5 
11204 Borough Park Brooklyn Medium 59,739 78,134 White 16.9 
11212 Brownsville Brooklyn Low 38,168 84,500 African American 18.4 
11217 Boerum Hill Brooklyn High 111,074 35,881 White 5.5 
11235 Brighton Beach Brooklyn Medium 62,842 79,132 White 15.9 
11239 Starrett City Brooklyn Low 34,784 13,393 African American 14.5 
10025 Upper West Side Manhattan High 115,200 94,600 White 8.6 
10026 Morningside 
Heights 
Manhattan Medium 64,751 34,003 African American 20.5 
10035 East Harlem Manhattan Low 45,516 33,969 Hispanic 17.6 
10038 South Street 
Seaport 
Manhattan High 124,271 20,300 White 12.9 
10009 Alphabet City Manhattan Medium 83,700 61,347 White 13.8 
10039 Upper 
Manhattan 
Manhattan Low 43,417 24,527 African American 25.0 
11697 Breezy Point Queens High 105,975 4,079 White 8.1 
11355 Flushing Queens Medium 59,124 85,871 Asian 14.9 
11692 Arverne Queens Low 44,816 37,337 African American 12.4 
11362 Little Neck Queens High 95,762 17,823 White 9.1 
11106 Astoria Queens Medium 61,476 38,875 White 21.1 
11433 Jamaica Queens Low 41,274 32,687 African American 21.7 
10307 Tottenville Staten Island High 113,102 14,096 White 5.4 
10305 Arrochar Staten Island Medium 79,425 41,749 White 11.6 
10302 Elm Park Staten Island Low 56,518 19,088 White 17.4 
10308 Bay Terrace Staten Island High 104,300 27,357 White 7.4 
10301 St. George Staten Island Medium 74,852 39,706 White 11.6 
10303 Mariners Harbor Staten Island Low 54,956 26,337 African American 17.4 
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Table 2. Summary Demographic Information and Number of Pharmacies Per Zip Code Income Levels in NYC 
 
Borough Income Status Mean 
Household 
Income ($) 
Total Population % Uninsured 
(2010) 
# Pharmacies 
Bronx High 
Medium 
Low 
  92,998 
  60,128 
  35,400 
  27,456 
118,315 
115,646 
  12.8 
  15.3 
  21.5 
   56 
  116 
  329 
Brooklyn High 
Medium 
Low 
106,404 
  61,291 
  36,476 
  69,217 
157,266 
  97,893 
   5.5 
  16.4 
  16.4 
  174 
  284 
  149 
Manhattan High 
Medium 
Low 
119,736 
  74,226 
  44,467 
 114,900 
   95,350 
   58,496 
  10.8 
  17.3 
  21.3 
  301 
  399 
  367 
Queens High 
Medium 
Low 
 100,869 
   60,300 
   43,045 
   21,902 
 124,746 
   70,024 
   8.6 
  18.0 
  17.1 
  186 
  204 
    70 
Staten Island High 
Medium 
Low 
 108,701 
   77,139 
   55,737 
   41,453 
   81,455 
   45,425 
   5.9 
  11.6 
  17.4 
    29 
    41 
    27 
High Income=Mean Household Income≥$80,000; Medium Income =Mean Household Income (X) $57,000 ≤ X<$80,000; Low 
Income=Mean Household Income <$57,000. 
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Table 3. Mean Drug Prices ($) by Zip Code 
 
Zip 
Code 
Income 
Level 
Number of 
Pharmacies 
Advair 
®250/50 
Proventil 
HFA® 
Metformin 
HCL 500mg 
Glipizide 
ER 5mg 
Amlodipine 
10mg 
Lisinopril 
10 mg 
Simvastatin 
20mg 
Atorvastatin 
10mg 
10471 High 40 293.85 53.74 40.65 13.78 44.79 22.86 84.80 141.80 
10466 Medium 53 306.96 55.96 28.37 13.35 44.61 23.77 84.80 145.15 
10453 Low 184 284.29 53.23 31.89 16.94 40.68 23.99 84.21 146.60 
10464 High 16 284.57 59.63 28.23 13.46 46.51 21.07 81.15 141.81 
10461 Medium 63 282.71 60.31 38.62 21.00 46.52 21.08 81.15 142.36 
10454 Low 145 283.76 70.76 40.35 17.97 43.76 22.15 94.57 144.49 
11231 High 68 272.47 51.88 27.76 13.42 52.73 24.51 95.10 144.13 
11204 Medium 184 308.94 49.82 48.23 17.71 53.76 28.89 91.34 146.44 
11212 Low 103 302.50 55.29 32.96 21.45 66.47 25.32 90.43 154.06 
11217 High 106 289.56 54.45 40.14 17.21 61.25 28.11 81.32 145.46 
11235 Medium 100 292.55 52.98 41.10 14.13 64.78 29.15 85.25 145.67 
11239 Low 46 300.31 65.47 33.32 19.93 48.17 32.22 89.73 146.79 
10025 High 142 304.46 55.65 40.03 20.43 40.03 19.97 64.28 140.36 
10026 Medium 168 298.55 66.62 29.41 14.63 41.16 29.84 90.03 149.42 
10035 Low 177 306.64 55.12 36.04 13.80 46.68 36.46 90.78 148.51 
10038 High 159 283.74 57.43 37.33 16.41 43.84 22.02 80.40 141.88 
10009 Medium 231 288.48 54.58 35.95 17.47 43.13 22.27 81.44 145.77 
10039 Low 190 312.40 56.98 44.12 18.11 58.18 28.41 92.32 148.69 
11697 High 164 284.45 53.54 41.11 14.59 51.57 28.35 85.26 142.73 
11355 Medium 68 267.84 59.36 28.76 17.84 40.52 18.95 79.84 140.52 
11692 Low 8 272.81 58.73 28.41 17.71 44.37 22.16 84.75 142.66 
11362 High 22 295.75 55.70 38.28 17.77 44.97 25.66 81.54 152.04 
11106 Medium 136 279.64 51.51 28.12 15.92 39.93 18.57 90.28 147.33 
11433 Low 62 281.69 57.73 24.54 17.86 52.73 18.32 79.35 146.42 
10307 High 17 295.43 48.79 28.68 17.21 61.59 24.62 86.20 143.49 
10305 Medium 19 304.67 51.52 32.11 16.88 62.10 25.33 93.15 141.76 
10302 Low 16 301.79 50.44 35.39 17.54 65.45 24.28 92.77 141.80 
10308 High 12 300.09 49.39 24.65 15.79 65.39 25.66 91.40 147.61 
10301 Medium 22 299.87 58.28 22.38 18.44 63.21 19.13 77.94 138.91 
10303 Low 11 305.34 48.75 22.37 17.30 63.21 24.52 90.12 139.48 
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Table 4. Mean Drug Prices (95%CI) Across Neighborhood Household Income Levels in NYC 
 
Drug High Income Medium  Income Low Income ANOVA 
F (p-values) 
Advair® 250/50 $290.44 
($284.62-$296.26) 
$293.02 
($284.75-$301.29) 
$295.15 
($286.92-$303.38 
0.377 (0.689) 
Proventil® 6.7gm
 
$54.02 
($51.93-$56.11) 
$56.09 
($52.90-$59.28) 
$57.25 
($53.14-$61.36) 
0.983 (0.387) 
Metformin HCL 
500mg 
$34.67 
($30.64-$38.70) 
$33.31 
($28.57-$38.05) 
$57.25 
($28.81-$$37.07) 
0.171 (0.843) 
Glipizide ER 5mg $16.01 
($14.61-$17.41) 
$16.74 
($15.32-$18.16) 
$17.76 
($16.64-$19.08) 
1.830 (0.180) 
Amlodipine 10mg $51.27 
($45.83-$56.71) 
$49.97 
($43.73-$56.21) 
$52.97 
($46.97-$58.97) 
0.250 (0.781) 
Lisinopril 10mg $24.28 
($22.54-$26.02) 
$23.70 
($20.96-$26.44) 
$25.78 
($22.50-$29.06) 
0.624 (0.543) 
Simvastatin 20mg $83.15 
($78.09-$88.21) 
$85.52 
($82.18-$88.86) 
$88.90 
($86.00-$91.80) 
2.128 (0.139) 
Atorvastatin 10mg $144.13 
($141.97-$146.29) 
$144.13 
($141.97-$146.29) 
$145.95 
($143.39-$148.51) 
0.802 (0.459) 
High Income=Mean Household Income ≥$80,000; Medium Income = Mean Household Income (X) $57,000 ≤ X< $80,000; 
Low Income=Mean Household Income < $57,000. 
 
 
 
 
                                                      Table 5.Mean Drug Prices (95% CI) Across New York City Boroughs 
 
Drug Bronx Brooklyn Manhattan Queens Staten Island ANOVA 
F (p-values) 
Advair®250/50 $289.36  
($281.76-
$296.96) 
$ 294.39 
($284.14-
$304.62) 
$299.05 
($290.20-
$307.90) 
$280.74 
($272.61-
$288.11) 
$301.03 
($298.30-
$304.10) 
4.23 (0.009) 
Proventil HFA® 
6.7gm
 
$58.93 
($53.75-$64.13) 
$54.98 
($50.59-$59.37) 
$57.66 
($54.14-$61.32) 
$56.10 
($53.63-$58.58) 
$51.10 
($48.30-$54.10) 
2.311 (0.08) 
Metformin HCL 
500mg 
$34.69 
($29.99-$39.99) 
$37.25 
($31-39-$43.11) 
$37.15 
($33.24-41.06) 
$31.54 
($26.29-$36.79) 
$27.60 
($23.29-$31.91) 
2.745 
(0.051) 
Glipizide ER 5mg $16.09 
($13.60-$18.56) 
$17.31 
($14.80-$19.82) 
$16.81 
($14.87-$18.75) 
$16.95 
($15.85-$18.05) 
$17.19 
($16.49-$17.89) 
0.249 
(0.907) 
Amlodipine 10mg $44.48 
($42.75-$46.21) 
$52.76 
($51.97-$63.75) 
$45.51 
($40.20-$50.80) 
$45.68 
($41-35-$50.01) 
$63.49 
($62.19-$64.79) 
16.907 
(<0.001) 
Lisinopril 10mg $22.49 
($21.47-$23.51) 
$28.03 
($25.79-$30.27) 
$28.03 
($21.51-$31.49) 
$22.00 
($18.64-$25.36) 
$23.93 
($21.99-$25.83) 
2.823 
(0.046) 
Simvastatin 20mg $85.12 
($81.16-$89.06) 
$88.86 
($84.97-$92.75) 
$83.21 
($74.77-$91.65) 
$83.50 
($80.20-$86.80) 
$88.60 
($83.97-$93.23) 
1.060 
(0.397) 
Atorvastatin 10mg $143.71 
($142.09-
$145.31) 
$147.10 
($144.26-
$149.92) 
$145.77 
($142.70-
$148.84) 
$145.29 
($141.94-
$148.62) 
$142.18 
($139.66-
$144.70) 
1.851 
(0.151) 
 
